📅 PUBMED DAILY TRIAGE — 2026-06-18

Window: 2026-06-17T09:00Z → 2026-06-18T09:00Z (CRDT) Topics scanned: 9 + sentinel | Candidates evaluated: ~191 | Articles kept: 18 High priority: 2 | Standard: 15 | Low/archive: 0 kept | Unsolicited finds: 1 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Cardiovascular-Metabolic (GLP-1 / SGLT2 / Cardiometabolic Risk)

TR-2026-06-18-001 · [PMID 42309121] · 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes · 9/10 · Lancet Diabetes Endocrinol → Largest real-world head-to-head comparison (n=45,093, Epic Cosmos EHR, 1,633 hospitals): tirzepatide achieved 13.2% composite weight+HbA1c target vs semaglutide 3.0% vs sleeve gastrectomy 24.0% at 1 year — tirzepatide showed 4.4× superiority over semaglutide for combined metabolic target; surgery led but with higher ED visit rates. Directly actionable for treatment selection in high-BMI T2D.

Rare Diseases with High Unmet Need

TR-2026-06-18-002 · [PMID 42308588] · Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study · 8/10 · EBioMedicine → First phase 1b data with 24-month follow-up for sevasemten (oral fast myosin ATPase inhibitor) in 12 adults with Becker MD: well-tolerated, durable reduction in muscle injury biomarkers from week 4, functional stabilization (NSAA stable) vs expected decline. First novel oral mechanism in BMD with extended safety data. Phase 2/3 ongoing.

Topics with zero 8+ articles today: T1 (Hematologic), T2 (CBC/ML), T3 (Liquid biopsy), T4 (AI/ML), T5 (Precision oncology), T6 (Novel therapeutics), T8 (Aging/longevity)

🟢⚪ STANDARD (5-7) — Top by Topic

T1 — Hematologic Malignancies

• TR-006 · [42309461] · Real-world anakinra prophylaxis for ICANS/CRS after CD19 CAR-T in R/R B-NHL (n=176, IPTW) · 7/10 · Transplant Cell Ther — Important negative finding: anakinra did NOT reduce severe ICANS; associated with 7× higher grade ≥3 infections; challenges off-label practice
• TR-009 · [42310437] · Ex vivo MABEL FIH dose selection for forimtamig T-cell bispecific in RRMM · 6/10 · Clin Pharmacol Ther — Novel patient-centric dose selection methodology, regulatory accepted
• TR-010 · [42309324] · Fluoroquinolone effect on arsenic metabolism/cardiotoxicity in APL + arsenic trioxide · 6/10 · Biochem Pharmacol — Clinically actionable drug interaction data for APL management
• TR-013 · [42309384] · IL4I1+ macrophage accumulation in advanced CTCL → immune escape · 5/10 · J Invest Dermatol
• TR-014 · [42309255] · Venetoclax + HMA synergy + metabolic remodeling in B-ALL (in vitro) · 5/10 · Mol Metab

T2 — CBC-Based Diagnostics + Machine Learning

• TR-017 · [42307087] · Preanalytical workflow for blood-based IR molecular fingerprinting · 5/10 · Anal Chem — T2 zero-signal streak broken at day 3 (marginal hit; see run notes)

T3 — Liquid Biopsy / ctDNA / cfDNA

• TR-008 · [42310468] · High-sensitivity ctDNA (NOIR-SS + molecular barcodes) for monitoring advanced urothelial carcinoma, n=15 · 6/10 · Cancer Med — Novel high-fidelity deep sequencing platform, feasibility data

T4 — AI/ML in Clinical Diagnostics

• TR-003 · [42309847] · Validation study: Hologic Genius AI Digital Diagnostics System for Pap test (n=1748; 98.5% concordance) · 7/10 · J Am Soc Cytopathol — Passed clinical validation threshold; supports deployment of AI-assisted cervical cancer screening
• [42309979] · AI-assisted prostate cancer MRI + PI-RADS v2.1: novice vs experienced reader comparison · 6/10 · J Magn Reson Imaging (not in kept set — see search log)

T5 — Precision Oncology / Genomic Medicine

• No unique standard articles above threshold (heavy T6 overlap). Best unique: CRISPR/Cas9 gRNA reprogramming (Nat Commun, 42309993, ~5/10, preclinical)

T6 — Novel Therapeutics

• TR-004 · [42310472] · ADCs in gynaecological cancers: opportunities and challenges · 7/10 · Nat Rev Clin Oncol — Comprehensive review of 3 approved ADCs; combination strategies + resistance mechanisms
• TR-005 · [42310313] · Phase I/II ICRA trial: tremelimumab + paclitaxel in ICI-refractory metastatic urothelial cancer (n=44; 26% ORR arm A) · 7/10 · Nat Commun
• [42310302] · IDH1-R132H + oncolytic HSV-1 in glioma → precision virotherapy (preclinical) · 5/10 · Nat Commun (sentinel/unsolicited)

T7 — Cardiovascular-Metabolic

• TR-001 · HIGH — see above
• TR-012 · [42307110] · Air pollution × genetic predisposition to BP/LDL-C on cardiovascular events (MR) · 6/10 · Eur J Prev Cardiol
• TR-015 · [42309157] · Comparative oral antidiabetics on MASLD progression in T2D (retrospective cohort) · 5/10 · Exp Clin Endocrinol Diabetes

T8 — Aging / Longevity

• TR-011 · [42309988] · Hippocampal GFAP in aging: associations with LATE-NC, tangles, and cognitive decline (Rush ADRC) · 6/10 · Alzheimers Dement
• TR-016 · [42308222] · REPROGRAM trial protocol: geroprotectors for biological aging (clinical trial protocol) · 5/10 · PLoS One

T9 — Rare Diseases

• TR-002 · HIGH — see above
• TR-007 · [42308225] · Functional profiling of 2,193 ASS1 missense variants → ClinVar VUS reclassification for citrullinemia type I (yeast deep mutational scan) · 5/10 · PLoS Genet

💡 UNSOLICITED FINDS

TR-SEN-001 · [42310302] · IDH1-R132H enhances oncolytic HSV-1 therapy via Nectin-1 upregulation and IFN suppression in glioma (Nat Commun, Chiocca/Cook/Freeman/Kuchroo, Harvard/Brigham) · 5/10 · Preclinical. IDH1-R132H proposed as predictive biomarker for CAN-3110 oncolytic virotherapy; TIGIT blockade combination enhances efficacy. Novel precision virology/oncology concept.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 8
• Drug Development: 3
• Diagnostics: 4
• Genomics/Precision Medicine: 2
• Prevention: 1

By evidence maturity:

• Exploratory: 14
• Validated: 3
• Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 18 | preprint: 0

Topics with zero 8+ articles this run: T1, T2, T3, T4, T5, T6, T8 (7 of 9 topics)

🔧 RUN NOTES

1. Window expansion: Not triggered (18 articles > 5 threshold).
2. Truncation: esummary responses truncated at 20KB for T1, T2, T4, T5, T6, T7, T8 batches. Top 7–14 IDs per T4 and T5 not fully reviewed. This may mean additional STANDARD articles were missed.
3. T2 zero-signal streak: 2 days (now broken at day 3 with marginal 5/10 hit). T2 query has an ongoing NCBI synonymy issue — "hematology" expands to hemorrhage/hematoma and hemorrhagic. Recommended fix next run: Add NOT hemorrhage[tiab] NOT hematoma[tiab] exclusion clause; use narrower terms ("hematology analyzer" OR "complete blood count" OR "leukocyte differential") with explicit ML terms.
4. T1 No HIGH articles: CAR-T anakinra negative finding (7/10) was best T1 result. Watchlist query is broad; dilution by non-leukemia results noted.
5. PMID 42310469 (T8 top result): Not reviewed due to fetch truncation. To be checked next run or as deferred.
6. PMID 42310438 excluded: Nat Med "CAR T cells take on precancers" identified as Comment/editorial — no abstract, excluded per default exclusion criteria.
7. T5/T6 overlap: Heavy cross-listing continues. Consider adding deduplication step by fingerprint before per-topic scoring.
8. 7-day rolling view (T2 zero-HIGH streak): Day 3. Action still needed per query refinement recommendation.